Catabasis Pharma (CATB) Tops Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Catabasis Pharmaceuticals Reports First Quarter 2016 Financial Results and Recent Corporate Highlights
May 12, 2016 4:10 PM EDT-- Edasalonexent (CAT-1004) as a Potential Treatment for Duchenne Muscular Dystrophy (DMD): MoveDMDSM Part B (Phase 2) Trial Initiated Following Positive Safety, Tolerability, Pharmacokinetic and NF-kB Biomarker Data from Part A --
-- CAT-2054 as a Potential Treatment for Nonalcoholic Steatohepatitis (NASH) and Hypercholesterolemia: Promising Pre-Clinical Data in NASH; Phase 2a Trial in Hypercholesterolemia Fully Enrolled --
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Catabasis... More
